Alpha Tau Posts Q2 Results, Completes Enrollment in First U.S. Pivotal Trial
DRTS has more than doubled off its 52-week low of $3.
Summary
Alpha Tau reported Q2 2026 financials and a slew of clinical milestones. The company completed enrollment in its first U.S. pivotal trial (ReSTART for cSCC) with 88 patients, a key de-risking event. Cash stands at $104.8 million, providing runway. The update also highlights the first immunocompromised patient treated in the ADMIRE study and the first glioblastoma patient treated outside the U.S. This follows a string of positive data readouts and the Tolmar partnership announced in June. The dense pipeline of catalysts, with major data readouts expected around year-end, keeps the stock in play.
At the time of this announcement, DRTS was trading at $13.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $3.00 to $14.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.